• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About
  • BCPS
  • Medicine and Media
  • Pharmacogenomics
  • Podcast
Digital PharmD

Digital PharmD

Informatics in Pharmacy

Ketoacidosis

August 12, 2018 By Dr. G, PharmD

Print Friendly, PDF & Email

Ketoacidosis is more common in type 1 diabetes than in type 2.  The goal treatment is to stop ketosis, not to normalize glucose.

Common symptoms: polyuria, polydipsia, vomiting, dehydration, weakness, altered mental status, coma, abdominal pain, Kussmaul respirations, tachycardia, hyponatremia, hyperkalemia

Treatment:

  1. Fluid replacement: start with 0.45-0.9% NS, change to 5% dextrose or dextrose containing saline when glucose is less than 200 mg/dl.
  2. Correct serum sodium(for every 100mg/dL increase over 100 in glucose, increase sodium by 1.6).  Usually, 0.9% NS, do not rapidly correct sodium ever.
  3. If potassium is less 3.3 mEq/L, replace KCl before giving insulin.
  4. Insulin: 0.1 unit/kg bolus and then infusion ONLY if KCl is greater than 3.3 mEq/L.  Keep glucose 150-200 mg/dl until DKA resolves.
  5. If pH <= 6.9 – Give bicarb over 1-2 hours
  6. DKA is resolved when serum glucose is less than 200 and 2 of the following:
    Venous pH >  7.3
    Bicarb 15 mEq or greater
    Anion gap of 12 mEq or less

If you prefer charts, here’s one I downloaded for my notes.

Filed Under: Endocrine Disorders Tagged With: acidosis, diabetes

Primary Sidebar

Newsletter

More to See

COVID-19 mRNA EUA Vaccine FAQs

December 29, 2020 By Dr. G, PharmD

What Makes a Good Vaccine? (Part 1)

October 20, 2020 By Dr. G, PharmD

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia bcps Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020

Footer

Medical Disclaimer

The medical information on this website is provided “as is” without any representations or warranties, express or implied. GoPharmD makes no representations or warranties in relation to the medical information on this website.

GoPharmD does not warrant that:

  • the medical information on this website will be constantly available, or available at all; or
  • the medical information on this website is complete, true, accurate, up-to-date, or non-misleading.
  • You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider.
  • If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider.

Recent

  • Johnson and Johnson Coronavirus EUA Vaccine FAQ
  • COVID-19 mRNA EUA Vaccine FAQs
  • What Makes a Good Vaccine? (Part 1)
  • COPD and Bronchitis
  • Asthma

Search

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia bcps Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020